Join
Live feed
·
PRReleasevia Quantisnow
Agilent Technologies Inc. logo

Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma

ByQuantisnow·Wall Street's wire, on your screen.
A· Agilent Technologies Inc.
Industrials

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track A (Agilent Technologies Inc.) and more on Quantisnow.